Keyphrases
Cyclosporine
100%
Squamous Cell Carcinoma (SqCC)
100%
Cutaneous Squamous Cell Carcinoma (cSCC)
100%
Ruxolitinib
100%
Induced Proliferation
100%
Interleukin-22 (IL-22)
87%
Organ Transplant Recipients
62%
Tumor Growth
37%
Janus Kinase 1 (JAK1)
37%
Squamous Carcinoma Cells
25%
JAK-STAT Pathway
25%
Tumor
12%
Metastasis
12%
Nude Mice
12%
Proliferative Response
12%
DNA Damage
12%
Differentially Expressed
12%
A431 Cells
12%
High Risk
12%
Allograft
12%
Tumor Volume
12%
Human Squamous Cell Carcinoma
12%
Systemic Treatment
12%
Immunosuppression
12%
Aggressive Behavior
12%
Pathway Genes
12%
JAK-STAT
12%
Cancer Targeting
12%
FDA-approved Drugs
12%
Innate Immunity Response
12%
P53 Regulation
12%
A431
12%
IL-22 Receptor
12%
Medicine and Dentistry
Cyclosporine
100%
Squamous Cell Carcinoma
100%
Skin Carcinoma
100%
Ruxolitinib
100%
Transplantation
62%
Tumor Progression
37%
Neoplasm
25%
Squamous Cell Carcinoma Cell
25%
Malignant Neoplasm
12%
Metastatic Carcinoma
12%
Receptor
12%
Protein P53
12%
Allograft
12%
Drive
12%
DNA Damage Response
12%
Innate Immunity
12%
Immunosuppressive Treatment
12%
Aggression
12%
Systemic Therapy
12%
A431 Cells
12%
Pharmacology, Toxicology and Pharmaceutical Science
Squamous Cell Carcinoma
100%
Skin Carcinoma
100%
Ciclosporin
100%
Ruxolitinib
100%
Tumor Growth
30%
Neoplasm
20%
Malignant Neoplasm
10%
Receptor
10%
Protein P53
10%
Nude Mouse
10%
Systemic Treatment
10%
Immunology and Microbiology
Squamous Cell
100%
Ciclosporin
100%
Transplant Procedure
50%
Squamous Cell Carcinoma Cell
20%
STAT1
20%
Nude Mouse
10%
DNA Damage Response
10%
P53
10%
Innate Immune System
10%
Allotransplantation
10%
Tumor Volume
10%
Immunosuppression
10%